Literature DB >> 19846277

Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis.

V Barak1, C Selmi, M Schlesinger, M Blank, N Agmon-Levin, I Kalickman, M E Gershwin, Y Shoenfeld.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune liver disease characterized by selective destruction of the intrahepatic bile ducts and highly specific serum anti-mitochondrial autoantibodies (AMA). Several studies have attempted to determine the cytokine pattern characterizing PBC, yet no definitive data have been gathered. The present study was designed to evaluate pro-inflammatory cytokines (IL-1beta, IL-6, TNFalpha), soluble IL-2 receptor (sIL-2R, e.g. soluble CD25), and complement components (C1q, C3, factor B, properdin) levels in sera from 84 patients with PBC and 41 controls. PBC was characterized by significantly higher levels of all pro-inflammatory cytokines when compared to controls; these included IL-1beta (433.3 +/- 13.2 vs. 316.6 +/- 14.7 pg/ml, P < 0.001), IL-6 (701 +/- 17.4 vs. 158 +/- 22.5 pg/ml, P < 0.001), TNFalpha (3.38 +/- 0.6 pg/ml vs. undetectable, P = 0.001), and sIL-2R (1527.1 +/- 106 vs. 566.4 +/- 28.7 U/ml, P < 0.001). Similarly, all complement components were also significantly higher in PBC compared to control sera. In conclusion, PBC sera manifest higher levels of sIL-2R and complement components and this may reflect a perpetuated immune activation. As expected, we also report that all major pro-inflammatory cytokine levels are enhanced in PBC. Further longitudinal analyses could demonstrate a correlation between these markers and disease stage or inflammatory activity, to predict histological staging, disease activity, and response to treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846277     DOI: 10.1016/j.jaut.2009.09.010

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  28 in total

Review 1.  Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature.

Authors:  Nicola Bizzaro; Giovanni Covini; Floriano Rosina; Paolo Muratori; Elio Tonutti; Danilo Villalta; Fiorenza Pesente; Maria Grazia Alessio; Marilina Tampoia; Antonio Antico; Stefan Platzgummer; Brunetta Porcelli; Lucia Terzuoli; Marco Liguori; Danila Bassetti; Ignazio Brusca; Piero L Almasio; Giuseppe Tarantino; Chiara Bonaguri; Paolo Agostinis; Elena Bredi; Renato Tozzoli; Pietro Invernizzi; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

2.  Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis.

Authors:  Weici Zhang; Masanobu Tsuda; Guo-Xiang Yang; Koichi Tsuneyama; Guanghua Rong; William M Ridgway; Aftab A Ansari; Richard A Flavell; Ross L Coppel; Zhe-Xiong Lian; M Eric Gershwin
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

Review 3.  Update on primary biliary cirrhosis.

Authors:  Pietro Invernizzi; Carlo Selmi; M Eric Gershwin
Journal:  Dig Liver Dis       Date:  2010-03-31       Impact factor: 4.088

Review 4.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

5.  Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity.

Authors:  Phornnop Naiyanetr; Jeffrey D Butler; Liping Meng; Janice Pfeiff; Thomas P Kenny; Kathryn G Guggenheim; Roman Reiger; Kit Lam; Mark J Kurth; Aftab A Ansari; Ross L Coppel; Marcos López-Hoyos; M Eric Gershwin; Patrick S C Leung
Journal:  J Autoimmun       Date:  2011-07-18       Impact factor: 7.094

6.  Immune-mediated bile duct injury: The case of primary biliary cirrhosis.

Authors:  Carlo Selmi; Andrea Affronti; Laura Ferrari; Pietro Invernizzi
Journal:  World J Gastrointest Pathophysiol       Date:  2010-10-15

7.  Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Authors:  Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat
Journal:  Hepatology       Date:  2016-10-12       Impact factor: 17.425

8.  Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease.

Authors:  Nancy Agmon-Levin; Ron Kopilov; Carlo Selmi; Udi Nussinovitch; María Sánchez-Castañón; Marcos López-Hoyos; Howie Amital; Shaye Kivity; Eric M Gershwin; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

9.  Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons.

Authors:  Meghan E Fitzpatrick; Mehdi Nouraie; Matthew R Gingo; Danielle Camp; Cathy J Kessinger; James B Sincebaugh; Andrew Clarke; John W Ries; Eric C Kleerup; Lawrence Kingsley; Alison Morris
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

10.  Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease.

Authors:  Majedeline Belghiti; Judith Estévez-Herrera; Carla Giménez-Garzó; Alba González-Usano; Carmina Montoliu; Antonio Ferrer-Montiel; Vicente Felipo; Rosa Planells-Cases
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.